Company Description
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B.
It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis.
The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors.
It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E.
Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.
Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Feb 19, 2004 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 405 |
| CEO | Ryan Spencer |
Contact Details
Address: 2100 Powell Street, Suite 720 EmeryVille, California 94608 United States | |
| Phone | 510 848 5100 |
| Website | dynavax.com |
Stock Details
| Ticker Symbol | DVAX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001029142 |
| CUSIP Number | 268158201 |
| ISIN Number | US2681582019 |
| Employer ID | 33-0728374 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ryan Spencer | Chief Executive Officer and Director |
| David F. Novack | President and Chief Operating Officer |
| Kelly MacDonald CPA | Senior Vice President and Chief Financial Officer |
| John L. Slebir | Senior Vice President and General Counsel |
| Dr. Robert Janssen M.D. | Chief Medical Officer and Senior Vice President of Clinical Development, Medical and Regulatory Affairs |
| Joseph Metzinger | Vice President and Chief Accounting Officer |
| Jeff P. Coon | Senior Vice President and Chief Human Resources Officer |
| Paul Cox | Vice President of Investor Relations and Corporate Communications |
| Donn Casale | Senior Vice President and Chief Commercial Officer |
| Dr. Dong Yu | Senior Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 25, 2025 | SCHEDULE 13G/A | Filing |
| Aug 21, 2025 | 8-K | Current Report |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 17, 2025 | SCHEDULE 13G/A | Filing |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 9, 2025 | DFAN14A | Filing |
| Jun 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |